Skip to main content Homepage

Monoclonal antibody therapy (mAb)

Provider Operations ManualManual para ProveedoresTest to Treat LocatorCOVID-19 Therapeutics Locator

Important Updates

  • The federal government has changed the reporting cadence for Evusheld, bebtelovimab, Paxlovid, and Lagevrio (molnupiravir) to twice per week, Mondays and Thursdays, by 11:59pm. A popup will appear in HPOP when ordering, if inventory is not reported.
  • Click here to join us for our new OHA Therapeutics Office Hours that are held every Monday from 2:00pm - 2:30pm PST. The purpose of these office hours are to provide HPoP updates, best practices, and other helpful information from OHA's Logistics team on COVID-19 therapeutics processes. This is an opportunity for providers to ask questions, provide feedback, and discuss topics with other providers.
  • Click here to view the June editiion of our new COVID-19 Therapeutics Newsletter to receive updates, allocation data, events and more. These will be released monthly and can be found under the "Additional Resources" section on this page.
  • Please review the ASPR webpage for updates regarding Bebtelovimab shelf-life extensions and other important federal updates.

  • Please place COVID-19 Therapeutics orders through Direct Ordering Requests (DOR) via the Health Partner Ordering Portal (HPOP). All providers are to submit order requests via HPOP going forward. If you have not placed orders before and need to be on-boarded to the ordering process, please complete the COVID-19 Therapeutics Provider Registration Survey. OHA has created materials to assist with this transition that can be found below.
    • Please review the HPoP supplements in order of priority. These can aslo be found on this page under the "Healthcare Provider Resources" section. 

​Tixagevimab/Cilgavimab (Evusheld)

  • ​Preexposure prevention of COVID-19
  • Given into the muscle
  • For people not currently infected, no recent exposure, and
    • Moderate to severe immunocompromise, or
    • Can't get vaccinated for medical reasons (severe allergy)


  • Treatment of mild-to-moderate COVID-19 illness
  • Given by vein, within 7 days of symptom onset
  • For people with a positive test, at high risk for severe COVID-19 and no access to other FDA-authorized treatments

All providers are now eligible to order both Euvhseld and Bebtelovimab. OHA remains committed to equitable distribution of all therapeutics, however, due to supply fluctuations, OHA may not be able to fulfill 100% of the courses requested. ​​​

​​​New Providers

Established Providers

  • Submit order requests directly in HPOP
  • Surveys are due on Wednesdays by 11:59 pm to be considered for the current weekly allocation. Surveys submitted after the due date will be considered for the next allocation cycle. 

Weekly federal allocations and provider requests Due to limitations in supply, Oregon Health Authority (OHA) is working to equitably distribute our federal allocation, which is updated weekly.

Sites receiving mAb therapySites listed below are those receiving shipments of mAb therapies in the most recent week. Sites may redistribute their allocation to other providers. This list is not indicative of how much product a location may have available at any given time. If you are seeking mAb therapy for yourself, please contact your provider.


Allocations are prioritized to ordering sites weekly, based on the following considerations:

  • Federally Qualified Health Centers & Tribal Health Clinics, which serve communities disproportionately impacted by COVID-19
  • County-level COVID-19 hospitalizations & cases 
  • Sites located in communities disproportionately impacted by COVID-19 (utilizing COVID-19 Community Vulnerability Index)
  • Site-level weekly utilization rate

Download the list

 Contact Us

 Healthcare Provider Resources

OHA Resources

COVID-19 Therapeutics Newsletters

Webinars for Providers

August 19, 2021 - OHA COVID-19 Senior Health Advisors Dawn Maunter, MD, MS and Shimi Sharief, MD, MPH

Watch the webinarDownload the slides

March 10, 2022 - OHA Outreach Coordinator Greg Desrosiers and Provider Panelists

Watch the webinarDownload the slides

HHS Resources

 Patient Resources

 Visit our treatments page